---
title: "INKT: Phase 2 trial of agenT-797 showed early clinical benefit; cash at $8.8M, net loss narrowed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295792601.md"
description: "Advanced to randomized Phase 2 trial for agenT-797 in acute lung injury, with early patients showing clinical improvement and no major adverse events. Cash position declined to $8.8M, net loss improved year-over-year, and a paid named-patient access program was launched internationally.Original document: MiNK Therapeutics, Inc. [INKT] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T11:42:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295792601.md)
  - [en](https://longbridge.com/en/news/295792601.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295792601.md)
generator: "portal-rs"
---

# INKT: Phase 2 trial of agenT-797 showed early clinical benefit; cash at $8.8M, net loss narrowed

Advanced to randomized Phase 2 trial for agenT-797 in acute lung injury, with early patients showing clinical improvement and no major adverse events. Cash position declined to $8.8M, net loss improved year-over-year, and a paid named-patient access program was launched internationally.

Original document: MiNK Therapeutics, Inc. \[INKT\] SEC 8-K Current Report — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [INKT.US](https://longbridge.com/en/quote/INKT.US.md)

## Related News & Research

- [MiNK Therapeutics (INKT) Q2 2026 Earnings Call: agenT-797 ARDS Trial Advances](https://longbridge.com/en/news/295902568.md)
- [GlucoTrack unit Lokahi Therapeutics expands ai2 Futures Lab collaboration with University of Georgia](https://longbridge.com/en/news/296614954.md)
- [Trinity Innovation leads angel round in Navi Therapeutics, which later closes A round worth several hundred million yuan](https://longbridge.com/en/news/296202609.md)
- [Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41](https://longbridge.com/en/news/296530942.md)
- [Rakovina Therapeutics adds Petra Hamerlik to board as Jeffrey Bacha retires](https://longbridge.com/en/news/296320749.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**